Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

Agriculture is not just a sector mdash;it is the heartbeat of Ghana rsquo;s economy, a living testament to the grit and ...

The Nigeria Natural Medicine Development Agency (NNMDA) has unveiled plans to train five million Nigerian youths in cassava ...

NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

The Nigerian Senate has advanced efforts to mandate the inclusion of cassava in flour production and its derivatives.

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

The Senate has passed for a second reading a bill that seeks the inclusion of 20 per cent high-quality cassava flour in wheat ...